These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35621089)

  • 21. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.
    Waksman R; Zumstein P; Pritsch M; Wittchow E; Haude M; Lapointe-Corriveau C; Leclerc G; Joner M
    EuroIntervention; 2017 Jul; 13(4):440-449. PubMed ID: 28262623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magmaris Resorbable Magnesium Scaffold Versus Conventional Drug-Eluting Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity-Score-Matching Comparison.
    de Hemptinne Q; Xaplanteris P; Guédès A; Demeure F; Vandeloo B; Dugauquier C; Picard F; Warne DW; Pilgrim T; Iglesias JF; Bennett J
    Cardiovasc Revasc Med; 2022 Oct; 43():28-35. PubMed ID: 35641364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
    La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Current Literature on Bioabsorbable Stents: a Review.
    Omar WA; Kumbhani DJ
    Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges of the newer generation of resorbable magnesium scaffolds: Lessons from failure mechanisms of the past generation.
    Seguchi M; Aytekin A; Lenz T; Nicol P; Alvarez-Covarrubias HA; Xhepa E; Klosterman GR; Beele A; Sabic E; Utsch L; Alyaqoob A; Joner M
    J Cardiol; 2023 Feb; 81(2):179-188. PubMed ID: 36122642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained Safety and Efficacy of Magnesium Reabsorbable Scaffold: 2-Year Follow-Up Analysis From First Magmaris Multicenter Italian Registry.
    Galli S; Troiano S; Palloshi A; Rapetto C; Pisano F; Aprigliano G; Leoncini M; Ravagnani P; Del Maestro M; Montorsi P
    Cardiovasc Revasc Med; 2022 Aug; 41():69-75. PubMed ID: 35256294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.
    Madanchi M; Cioffi GM; Attinger-Toller A; Wolfrum M; Moccetti F; Seiler T; Vercelli L; Burkart P; Toggweiler S; Kobza R; Bossard M; Cuculi F
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34518287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
    Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: what have we learned from randomized-controlled clinical trials?
    Rizik DG; Hermiller JB; Simonton CA; Klassen KJ; Kereiakes DJ
    Coron Artery Dis; 2017 Jan; 28(1):77-89. PubMed ID: 27561169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.
    Nef HM; Wiebe J; Schmidt G; Möllmann H; Boeder NF; Dörr O; Bauer T; Blachutzik F; Liebetrau C; Elsässer A; Foin N; Hamm CW
    Herz; 2020 Dec; 45(Suppl 1):95-104. PubMed ID: 31209520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry.
    Dawson LP; Dinh D; Montalto S; Duffy SJ; Dick R; Gutman J; Brennan A; Carruthers H; Doyle J; Stub D; Whitbourn R; Cox N; Cooke J; Gooley R; Hiew C; Reid C; Lefkovits J;
    Heart Lung Circ; 2020 Oct; 29(10):1440-1448. PubMed ID: 31843365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent　- A Randomized Comparison Through 5 Years in Japan.
    Kozuma K; Tanabe K; Hamazaki Y; Okamura T; Ando J; Ikari Y; Nakagawa Y; Kusano H; Ediebah D; Kimura T;
    Circ J; 2020 Apr; 84(5):733-741. PubMed ID: 32213737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience.
    Costopoulos C; Crowson MC; Brown AJ; Braganza DM; Bennett MR; Hoole SP; West NE
    Cardiovasc Revasc Med; 2015 Dec; 16(8):461-4. PubMed ID: 26440767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS.
    Hommels TM; Hermanides RS; Berta B; Fabris E; De Luca G; Ploumen EH; von Birgelen C; Kedhi E
    Cardiovasc Diabetol; 2020 Oct; 19(1):165. PubMed ID: 33008407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
    Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
    Stone GW; Ellis SG; Gori T; Metzger DC; Stein B; Erickson M; Torzewski J; Williams J; Lawson W; Broderick TM; Kabour A; Piegari G; Cavendish J; Bertolet B; Choi JW; Marx SO; Généreux P; Kereiakes DJ;
    Lancet; 2018 Oct; 392(10157):1530-1540. PubMed ID: 30266412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.